European CHMP adopts positive opinion on Gilead’s Type II variation application for Truvada
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Gilead Sciences' Type II variation application for Truvada for reducing the risk of sexually acquired HIV.
Click on this link for more information.
